A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid , and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: A preliminary study

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 12, 2014, Pages 704-712

  Chwist, Alina ^a   Hartleb, Marek ^a   Lekstan, Andrzej ^a   Kukla, Michal ^a   Gutkowski, Krzysztof ^a   Kajor, Maciej ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HAPTOGLOBIN; HYALURONIC ACID; INSULIN; INTERLEUKIN 6; IRON; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TISSUE POLYPEPTIDE ANTIGEN; UNCLASSIFIED DRUG; ZONULIN; CHOLERA TOXIN; PEPTIDE; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ERYTHROCYTE COUNT; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HUMAN; INSULIN BLOOD LEVEL; IRON BLOOD LEVEL; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PREVALENCE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; BLOOD; COMPARATIVE STUDY; FIBROSIS; LIVER; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PILOT STUDY; YOUNG ADULT;

ADIPONECTIN; ADULT; AGED; CHOLERA TOXIN; FEMALE; FIBROSIS; HAPTOGLOBINS; HUMANS; HYALURONIC ACID; INTERLEUKIN-6; LEPTIN; LIVER; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NON-ALCOHOLIC FATTY LIVER DISEASE; PEPTIDES; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84920012931     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2558     Document Type: Article

References (35)

1. Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013; 5: 1544-1560.
2. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34: 274-285.
3. Ziolkowski A, Wylezol M, Kukla M, et al. The comparison of scoring scales for liver biopsy assessment in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2005; 15: 1309-1314.
4. Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol. 2012; 10: 661-668.
5. Zein CO, Edmison JM, Schluchter M, et al. NASH predictive index (NPI) for use in patients with nonalcoholic fatty liver disease. Hepatology. 2007; 46: 747A.
6. Poynard T, Ratziu V, Charlotte F, et al; LIDO study group; CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of nonalcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006; 6: 34.
7. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010; 52: 913-924.
8. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008; 57: 1441-1447.
9. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45: 846-854.
10. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and Fibrotest. Hepatology. 2007; 46: 32-36.
11. Caviglia GP, Touscoz GA, Smedile A, et al. Noninvasive assessment of liver fibrosis: Key messages for clinicians. Pol Arch Med Wewn. 2013; 124: 329-335.
12. Kosmalski M, Kasznicki J, Drzewoski J. Relationship between ultrasound features of nonalcoholic fatty liver disease and cardiometabolic risk factors in patients with newly diagnosed type 2 diabetes. Pol Arch Med Wewn. 2013; 123: 436-442.
13. Abenavoli L, Luigiano C, Guzzi PH, et al. Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease. Panminerva Med. 2014; 56: 189-193.
14. Kukla M, Mazur W, Buldak RJ, Zwirska-Korczala K. Potential role of leptin, adiponectin and three novel adipokines-visfatin, chemerin and vaspinin chronic hepatitis. Mol Med. 2011; 17: 1397-1410.
15. Kukla M, Ciupinska-Kajor M, Kajor M, et al. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Pol J Pathol. 2010; 61: 147-153.
16. Miele L, Marrone G, Lauritano C, et al. Gut-liver axis and microbiota in NAFLD: Insight pathophysiology for novel therapeutic target. Curr Pharm Des. 2013; 19: 5314-5324.
17. Fasano A. Intestinal permeability and its regulation by zonulin: Diagnostic and therapeutic implications. Clin Gastroenterol Hepatol. 2012; 10: 1096-1100.
18. Zak-Golab A, Kocelak P, Aptekorz M, et al. Gut microbiota, microinflammation, metabolic profile, and zonulin concentration in obese and normal weight subjects. Int J Endocrinol. 2013; 2013: 674106.
19. International Diabetes Federation. IDF worldwide definition of the metabolic syndrome. www.idf.org. Accessed 2014.
20. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41: 1313-1321.
21. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34: 274-285.
22. Chen J, Zhu Y, Zheng Q, et al. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res. 2014; 44: 854-862.
23. Moreno-Navarrete JM, Sabater M, Ortega F, et al. Circulating zonulin, a marker of intestinal permeability, is increased in association with obesityassociated insulin resistance. PLos One. 2012; 7: E37160.
24. Kamada Y, Akita M, Takeda Y, et al. Serum fucosylated haptoglobin as a novel diagnostic biomarker for predicting hepatocyte ballooning and nonalcoholic steatohepatitis. PLoS One. 2013; 8: E66328.
25. Misra S, Singh B. Insulin resistance and hypothyroidism: A complex relationship in non-alcoholic fatty liver disease. J Indian Med Assoc. 2013; 111: 324-326.
26. Sowa JP, Heider D, Bechmann LP, et al. Novel algorithm for non-invasive assessment of fibrosis in NAFLD. PLoS One. 2013; 8: E62439.
27. Kitade M, Yoshiji H, Noguchi R, et al. Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. World J Gastroenterol. 2009; 15: 5193-5199.
28. Auguet T, Terra X, Porras JA, et al. Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. Clin Biochem. 2013; 46: 202-208.
29. Genc H, Dogru T, Kara M, et al. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol. 2013; 12: 548-555.
30. Aller R, de Luis DA, Izaola O, et al. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci. 2009; 54: 1772-1777.
31. Gaddipati R, Sasikala M, Padaki N, et al. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Ann Hepatol. 2010; 9: 266-270.
32. Raszeja-Wyszomirska J, Szymanik B, Lawniczak M, et al. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2010; 10: 67.
33. McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010; 59: 1265-1269.
34. Ratziu V, Gira P, Charlotte F, et al. Liver fibrosis in overweight patient. Gastroenterology. 2000; 118: 1117-1123.
35. Kruger FC, Daniels CR, Kidd M, et al. APRI: A simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J. 2011; 101: 477-480.